TUDCA vs UDCA: Which One Should You Take?

Shoppers reach for TUDCA capsules and wonder why doctors prescribe UDCA instead — same family, different shelves. The confusion is understandable: TUDCA is the taurine-conjugated form of UDCA, and both are hydrophilic bile acids that may support bile flow. But one is a prescription drug with an established clinical record and regulated purity, and the other is a supplement with a real but narrower human evidence base — including, notably, one head-to-head trial that found them comparable for PBC (Ma et al., 2016). This guide compares what they are, what the evidence shows, doses, safety — and which one fits your situation.

About TUDCA

TUDCA (tauroursodeoxycholic acid) is a water-soluble bile acid and the taurine-conjugated form of UDCA. Per OrganicAlt's own remedy page, it is a bile salt used in Chinese medicine for centuries that may help dissolve gallbladder sludge, protect liver cells from toxic bile acids, and reduce endoplasmic reticulum (ER) stress — a driver of liver disease. It is sold as a supplement in the US, not a drug, which means no FDA-approved indications and variable manufacturing quality (note: TUDCA is a prescription drug in some countries, including Italy and China — the supplement framing here is for the US audience).

Its proposed mechanisms: promoting bile flow by displacing toxic hydrophobic bile acids, stabilizing cell membranes against bile-acid-triggered damage, and acting as a "chemical chaperone" that reduces ER stress in mouse and cell models (Ozcan et al., Science 2006, DOI 10.1126/science.1128294 — animal work, not human trials). TUDCA is more hydrophilic than UDCA, and one review suggests this could favor intestinal and liver uptake — but no direct human bioavailability comparison has been published, so treat "better absorbed" as a marketing claim, not an established fact.

What the human trials show: TUDCA has been studied in human trials for diagnosed conditions, and its record is more substantial than most supplement marketing suggests:

• Head-to-head vs UDCA: Ma et al. (2016) randomized 199 Chinese PBC patients to TUDCA 250 mg three times daily vs UDCA 250 mg three times daily for 24 weeks; alkaline-phosphatase reduction of >25% was achieved by 75.97% vs 80.88% (p=0.453), with comparable adverse-event rates. This is the strongest TUDCA trial published — but it tested a diagnosed disease population, not general wellness use.
• Dose-response in PBC: Crosignani et al. (1996) randomized 24 PBC patients to 500, 1,000, or 1,500 mg/day TUDCA for 6 months; liver enzymes fell within the first month at all doses, "diarrhea was the only side effect," and ~10 mg/kg/day was suggested for long-term studies.
• Metabolic: Kars et al. (2010) randomized 20 obese adults to 1,750 mg/day TUDCA vs placebo for 4 weeks; hepatic and muscle insulin sensitivity improved ~30%.
• Neurological: Elia et al. (2016) ran a phase IIb trial of TUDCA 2 g/day with riluzole in ALS for 54 weeks, finding slower functional deterioration. Note that the TUDCA-containing ALS drug AMX0035 (Relyvrio) showed benefit in the phase 2 CENTAUR trial but failed its phase 3 PHOENIX primary endpoint and was voluntarily withdrawn from the US and Canada on April 4, 2024.

For general liver or gallbladder support in healthy people, the human evidence base remains thin — these trials are all in diagnosed disease or specific conditions.

About UDCA

UDCA (ursodeoxycholic acid) is the prescription-drug sibling — sold under brand names like Urso 250 / Urso Forte and Actigall. The approved indications are split between the two products:

• Urso 250 / Urso Forte — FDA-approved for primary biliary cholangitis (PBC), a chronic autoimmune liver disease (DailyMed label, January 2023)
• Actigall — FDA-approved for (1) dissolution of radiolucent, noncalcified gallbladder stones <20 mm in patients for whom elective cholecystectomy would otherwise be indicated but who have increased surgical risk or refuse surgery (safety beyond 24 months not established), and (2) prevention of gallstone formation in obese patients experiencing rapid weight loss (DailyMed label, May 2018)

Because it is a regulated drug, UDCA carries the things TUDCA lacks: a verified purity standard, standardized dosing, and a large clinical safety database built over decades of prescribed use. Clinicians dose it by body weight — per the FDA labels, 13–15 mg/kg/day in two to four divided doses with food for PBC (Urso), and 8–10 mg/kg/day in 2 or 3 divided doses for gallstone dissolution (Actigall).

Important boundary: UDCA is a treatment for diagnosed disease under medical supervision. It is not sold over the counter, and its record does not transfer to TUDCA — related is not the same, and milligram equivalence across supplement and prescription products is not established.

Head-to-Head Comparison

Dosage Guide

Doses below are context, not prescriptions. Bile acids are physiologically potent — start low and escalate only with guidance.

Form notes: As an unregulated supplement, TUDCA quality varies — prefer third-party-tested products. UDCA is manufactured to pharmaceutical standards by definition. Never dose-convert between the two: milligram equivalence across supplement and prescription products is not established.

Timing: The site's TUDCA guide recommends taking it with meals to reduce GI upset. Prescription UDCA is taken with food in divided doses per both FDA labels (Urso: two to four divided doses with food; Actigall: 2 or 3 divided doses).

Safety & Interactions

Shared core caution: both are bile acids, so bile-duct obstruction is a hard stop without medical supervision — mobilizing a stone into the common bile duct can become a surgical emergency. The site's TUDCA page flags rare gallstone mobilization and excessive doses (>3,000 mg/day, the site's own caution threshold) causing diarrhea and GI upset.

TUDCA — less studied as a supplement. Most common effects are dose-dependent GI upset: loose stool, diarrhea, stomach cramping. Long-term human safety data at supplement doses is limited; much of the reassurance comes from UDCA's prescription record — a related but different compound. People with gallstones, gallbladder disease, bile-duct issues, or who are pregnant should use only under practitioner guidance.

UDCA — decades of monitored clinical use. The Actigall label's trial tables list GI events — diarrhea (27.1% vs 21.4% placebo in the dissolution trials; 25.2% vs 20.9% in the prevention trials), abdominal pain, nausea, dyspepsia — at rates modestly above placebo; Urso Forte postmarketing lists abdominal discomfort, diarrhea, and nausea. Rare reports include hypersensitivity reactions (Urso Forte label §6.2: facial edema, urticaria, angioedema, laryngeal edema). Because it's prescribed, the safety story is managed by the clinician — blood work, imaging, and contraindication screening are part of the package.

Interactions: Per the FDA labels — bile-acid sequestering agents (cholestyramine, colestipol) can reduce UDCA absorption; aluminum-based antacids may do the same; estrogens and oral contraceptives may counteract its effectiveness. Anyone on prescriptions — especially with liver or gallbladder diagnoses — should loop in their doctor or pharmacist before adding a bile-acid supplement to a UDCA regimen, or either compound on its own.

Which Should You Choose?

• You have a diagnosed liver or gallbladder condition (PBC, cholestasis, cholesterol gallstones) → UDCA: the only one with approved indications, pharmaceutical purity, and a clinical record behind it. Discuss with your hepatologist or gastroenterologist.
• You're generally healthy and want OTC bile-flow support → TUDCA: the accessible supplement option — but with practitioner guidance, starting at 250 mg, and eyes open about the evidence base (real but limited to diagnosed-condition trials, not general wellness).
• You're already prescribed UDCA → Do not stack TUDCA on top without your prescribing clinician's explicit direction; both act on the same bile-acid pool.
• Budget and quality control matter most → UDCA (prescription; regulated, often insured) beats any supplement on purity per dollar.

Short version: UDCA is the clinician's tool; TUDCA is the supplement shopper's tool. The one head-to-head trial (Ma 2016) found them comparable for PBC on biochemical response — but comparability in that trial doesn't make them interchangeable in practice: prescription status, purity standards, approved indications, and clinician oversight still separate them.

Can You Take Them Together?

No published trial has studied the combined safety or benefit of TUDCA + UDCA — PubMed and ClinicalTrials.gov searches turn up head-to-head comparisons and combination trials with other drugs, but no co-administration trial. Since TUDCA is UDCA's taurine conjugate, stacking them mostly adds more of the same bile-acid pool — potentially compounding dose-dependent GI effects without evidence of extra benefit. If you're on prescription UDCA, adding TUDCA is a dose change, not a combination therapy: only your prescriber should make that call. Never self-stack against a prescription.

📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.

Explore the Full Remedy Database

Browse 500+ organic alternatives for health, wellness, and natural living.